Working… Menu

Adipose-Derived Stromal Cells (ASC's) for Pressure Ulcers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02375802
Recruitment Status : Active, not recruiting
First Posted : March 3, 2015
Last Update Posted : October 7, 2019
Information provided by (Responsible Party):
Houssam Farres, M.D., Mayo Clinic

Brief Summary:
This pilot study of 12 patients will test the safety and efficacy of applying autologous, adipose-derived stromal cells (ASCs), uncultured, on a Stage III or IV pressure ulcer or diabetic foot ulcers. Patients will undergo a minimal risk liposuction procedure to withdraw 50-100 cc of adipose tissue. The tissue would be processed to extract the stromal layer of cells that contain stem cells. The ASCs would be injected into a fibrin sealant to be applied to the wound. Patients would be followed for 6 weeks to assess wound healing and tolerance of the treatment.

Condition or disease Intervention/treatment Phase
Pressure Ulcer Biological: Adipose-derived stromal cells Drug: Adipose-derived stromal cells Phase 1

Detailed Description:
Wound healing for Stage III and IV pressure ulcers or diabetic foot ulcers can take four to six weeks or longer and cost upwards of $40,000 to treat. Past studies have shown that adipose tissue contains progenitor cells or regenerative cells that can release multiple angiogenic growth factors and cytokines including vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF) and chemokine stromal cell-derived factor-1 (SDF-1). A current literature review revealed that there is research related to use of stem cells to enhance wound healing, in particular with ischemic or radiation-induced ulcers. However, there is limited research completed on use of stem cells or ASCs with pressure ulcers. The goal is to heal pressure ulcers faster and prevent further complications using the patient's own natural ASCs.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : July 2015
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Experimental
Liposuction will be done to extract 50-100 cc of adipose tissue which will be processed to obtain the stromal cells. The adipose-derived stromal cells will be injected into a fibrin sealant applicator and applied to the wound (intervention), Patients will receive 5.0x106 ASCs per cubic centimeter of wound area. The wound will be dressed with an occlusive dressing and soft silicone dressing. The dressing will remain in place for one week (minimally, 3 days). Follow-up will occur weekly for 6 weeks.
Biological: Adipose-derived stromal cells
Adipose-derived stromal cells contain stem cells which have been successful in enhancing wound healing. The product used as the carrier is a fibrin sealant called TISSEEL. Pre-pilot testing was done to verify viability of the stromal cells for up to 72 hours in the fibrin sealant.
Other Name: ASC's

Drug: Adipose-derived stromal cells

Primary Outcome Measures :
  1. Free of wound infection [ Time Frame: one week ]
    Symptoms include fever along with new or increasing pain, erythema, local warmth, swelling, purulent discharge, and/or malodor

Secondary Outcome Measures :
  1. Liposuction procedure without complication [ Time Frame: one week ]
    Signs of adverse reactions to the liposuction procedure include an allergy to the Hunstad solution, infection at the puncture wound site or risk of bleeding at the puncture wound site. Risks include bleeding or infection at the site and bruising for approximately one week. No adverse consequences of fluid overload have been associated with low volume liposuction.

  2. Improved wound healing [ Time Frame: weekly observation for 6 weeks ]
    Wound healing is greater than 20% healing within two weeks documented by measurement of the wound bed or wound healing to less than the dermal layer documented by photography and agreement of healing between research nurse and wound physician consultant. Would not expect deterioration to a more severe level of tissue injury

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  • Males and females
  • Stage III pressure ulcers measuring 5 cc - 36 cc in volume (as measured by filling the wound with Normal Saline).
  • Inpatient or outpatient treatment of pressure ulcers
  • Diabetic Foot Ulcer Stage 1 or 2 of any size
  • Co-morbidities may include:

    • Peripheral Vascular Disease (PVD)
    • Coronary Artery Disease (CAD)
    • Chronic Renal Disease (CRD)
    • Chronic Liver Disease (CLD)
    • Hypertension (HTN)
    • Diabetes
  • The ability of subjects to give appropriate consent or have an appropriate representative available to do so
  • The ability of subjects to return for weekly wound assessments

Exclusion Criteria

  • Patients with allergies to TISSEEL, Tegaderm, or silicon
  • Diabetics with poor glucose metabolic control (HbA1c > 9)
  • Target wounds that are in close proximity to potential cancerous lesions
  • Patients who require Negative Pressure Wound Therapy (NPWT), limb amputation, or surgical intervention at the target wound at the time of screening
  • Wounds located on the face
  • Patients with Stage 5 or 6 Peripheral Vascular disease (specifically, wounds that are caused by peripheral vascular disease such as leg ulcers)
  • Wounds caused by diabetes mellitus (diabetic foot ulcers).
  • BMI of <16 Clinical signs of critical colonization or local infection
  • Prolonged (> 6 months) use of steroids
  • Patients on active regimen of chemotherapy
  • Patients receiving radiation in proximity of wound
  • Decompensated chronic liver disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02375802

Layout table for location information
United States, Florida
Mayo Clinic in Florida
Jacksonville, Florida, United States, 32224
Sponsors and Collaborators
Mayo Clinic
Layout table for investigator information
Principal Investigator: Houssam Farres, MD Mayo Clinic

Additional Information:
Publications of Results:

Other Publications:
Layout table for additonal information
Responsible Party: Houssam Farres, M.D., Consultant and Vascular Surgeon, Mayo Clinic Identifier: NCT02375802     History of Changes
Other Study ID Numbers: 14-002855
First Posted: March 3, 2015    Key Record Dates
Last Update Posted: October 7, 2019
Last Verified: October 2019
Keywords provided by Houssam Farres, M.D., Mayo Clinic:
Stem cells
Additional relevant MeSH terms:
Layout table for MeSH terms
Pressure Ulcer
Pathologic Processes
Skin Ulcer
Skin Diseases
Fibrin Tissue Adhesive